Leonard Lothstein

Leonard Lothstein has been President and CEO of Paradox since its founding in late 2010. He also maintains tenured faculty appointments at the University of Tennessee Health Science Center in the Departments of Pathology (College of Medicine) and Pharmaceutical Sciences (College of Pharmacy), is currently a member of the UTHSC Medicinal Chemistry Core Advisory Board and was the founder and former Director of the UT Center for Anticancer Drug Research and Director of the Experimental Therapeutics at The UT Center for Cancer Research. Dr. Lothstein has 35 years of bench research experience in the areas of anticancer drug development, anthracycline pharmacology, and anticancer drug resistance, which has been supported by the National Institutes of Health, American Cancer Society, The Susan G. Komen Foundation, The Pharmaceutical Manufacturers Association Foundation, and the Milheim Foundation for Cancer Research. Dr. Lothstein has served as a consultant on multiple National Institutes of Health review panels and study sections. Dr. Lothstein earned a B.A. in Biology from Bowdoin College and Ph.D. in Molecular Biology from Vanderbilt University. He completed post-graduate training as a National Cancer Institute-funded fellow at both The Memorial Sloan Kettering Cancer Center and The Belfer Institute for Advanced Biomedical Studies at The Albert Einstein College of Medicine in NY.